Publication | Closed Access

Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation

InflammationAnti-inflammatoryMedicineImmunologyGastroenterologyPathologyCell ProliferationPharmacotherapyUlcerative ColitisColon CancerPharmacology